Given a paragraph, generate a claim that is supported by the given paragraph. 1) The claim must contain information from within the paragraph. 2) A sentence within the paragraph can be used as a claim. 3) The claim should not have contradictions within the paragraph. 4) The claim should be at most one sentence long.

Q: Leaf appeared Thursday at C.M. Russell High School in Great Falls for the first time in more than 20 years, The Great Falls Tribune reported Friday. In a speech titled, “Lying to Myself,” Leaf discussed his football career as a star at Washington State University, Heisman Trophy finalist and second-overall pick in the 1998 NFL draft by the San Diego Chargers. Four years later he was out of professional football and became addicted to prescription pills, which led to burglary and drug charges and a prison sentence, Leaf said. He recalled attending a boxing match in Las Vegas in the time shortly after hanging it up in the NFL and being booed loudly by the crowd as the announcer recognized celebrities in attendance. At an after-fight party, he took a Vicodin, and for the next eight years, kept trying to chase that high, he said. “I was a drug addict long before I ever took a drug,” Leaf said. “I didn’t know any better.” Leaf’s goal in telling his story was to connect with the audience and “try to give back to a community that I took so much from and victimized,” he said. He also spoke about the need for more discussion of mental health issues in Montana. “There is a mental health epidemic in this state,” Leaf said. “We need to come together as a community.” He does not practice a specific religion but spoke of spirituality, community and accountability. Leaf found his calling working as an assistant to a substance abuse counselor in prison, he said. He is now a program ambassador for Transcend Recovery, an addiction treatment center in Los Angeles where he worked after getting sober. As a pro athlete, “I was making $5 million a year and was miserable,” Leaf said. “Now, I was making $15 an hour and felt valued.” ___ Information from: Great Falls Tribune, http://www.greatfallstribune.com

A: Former NFL player Ryan Leaf gives speech on  substance abuse.
****
Q: A popular meme appearing in January 2019 presented a series of statements attributed to U.S. President Donald Trump on the topic of abortion. The meme, with its judicious use of quotation marks, accurately reflected excerpts of Trump’s videotaped remarks to be shown in conjunction with the 18 January 2018 March for Life:  However, these excerpts were presented out of order and in one case repeated the same section of text twice, reflecting a certain amount of artistic license. Presented below are Trump’s full remarks, with the relevant sections highlighted and numbered to reflect the four excerpts, and their order, as presented in the meme:  I am very proud to welcome tens of thousands of families, students, and people of all faiths and backgrounds to our nation’s capital for the 46th annual March For Life. This is a movement founded on love and grounded in the nobility and dignity of every human life. When we look into the eyes of a newborn child, we see the beauty and the human soul and the majesty of God’s creation (4). We know that every life has meaning and that (4) every life is worth protecting (3, 4), As president, I will always defend the first right in our Declaration of Independence — the right to life. During my first week in office, I reinstated the Mexico City Policy. We have taken bold action to protect the religious freedoms for doctors, nurses, and charities like the Little Sisters Of The Poor We issued a new proposal to prohibit Title Ten taxpayer funding from going to any clinic that performs abortions. We are supporting the loving choice of adoption and foster care, including through the support of faith-based adoption services. And I am supporting the U.S. Senate’s effort to make permanent the Hyde Amendment, which prohibits taxpayer funding for abortion in spending bills. Today I have signed a letter to Congress to make clear that if they send any legislation to my desk that weakens the protection of human life, I will issue a veto. (1) And we have the support to uphold those vetoes. Every child is a sacred gift from God (2). As this year’s March For Life theme says, each person is unique from Day One. That is a very important phrase. Unique from Day One. And so true. I want to thank Americans who traveled all across the country to march for life, and I especially want to thank so many young people who give us hope for the future. Together we will work to save the lives of unborn children, so they have a chance to live and to love, to thrive and to dream, and to bless our nation and reach their full and glorious potential. Thank you. God bless you and your families, and God bless America.

A: President Donald Trump said: “I have signed a letter to Congress to make clear that if they send any legislation to my desk that weakens the protection of human life, I will issue a veto … Every child is a sacred gift from God … Every life is worth protecting … We know that every life has meaning and that every life is worth protecting.”
****
Q: The company’s forecast implies a potential $3 billion upgrade to the consensus estimate from analysts and marks an attempt to call a bottom to a sales decline driven by the loss of exclusivity on several top-selling medicines. Britain’s second-biggest drugmaker is already suffering from generic competition to its antipsychotic Seroquel, while its Nexium treatment for excess stomach acid loses U.S. patent cover this year. Top-selling Crestor, for high cholesterol, faces competition from cheap copycat drugs in 2016. The patent expiries leave AstraZeneca’s sales on a near-term downward spiral at a time when most of its rivals have put their biggest patent losses behind them. Shares in the group rose 1.6 percent by 1215 GMT on the more upbeat outlook, against a 0.3 percent decline for the European healthcare sector. Chief Executive Pascal Soriot, who has been leading the company for a little more than a year, will set out the new revenue guidance in a presentation at the J.P. Morgan Healthcare conference in San Francisco later on Tuesday. The company will then give a more detailed update on its progress in full-year results on February 6. The consensus of analyst forecasts compiled by Thomson Reuters is for 2017 revenue of $22.5 billion, down from the $25.8 billion estimated for 2013. However, a number of the 2017 forecasts pre-date the diabetes drug deal struck last month that is already expected to add some $1 billion to $2 billion to annual revenue. Citigroup analyst Andrew Baum said the positive medium-term outlook reinforced his “more constructive thesis” for the stock, adding that he expects Soriot to strike more earnings-boosting deals this year. Panmure Gordon’s Savvas Neophytou remains more wary, pointing out that Soriot’s predecessor, David Brennan, had made a similar attempt to talk up AstraZeneca’s longer-term prospects. “In our view, management is stepping onto thin ice with this same sort of guidance,” Neophytou said, pointing out the previous management’s failure to hit its forecasts. AstraZeneca has become more confident about its revenue outlook after the $4 billion deal last month to buy Bristol-Myers Squibb’s share of a diabetes joint venture. The acquisition is expected to complete in the first quarter of 2014 and will boost sales immediately. Mark Clark of Deutsche Bank said this was set to lift analysts’ revenue forecasts significantly, suggesting that a more realistic “adjusted consensus” for 2017 was around $24.3 billion rather than $22.5 billion. Soriot has been striking a number of bolt-on deals to refill the company’s thin pipeline of new medicines and accelerating in-house research programs. The group now has 11 new-drug programs in late-stage Phase III testing, almost double the number a year ago, and 27 in Phase II. Hopes are particularly high for its cancer research, where it has started trials for immunotherapy combination treatments for which the first results are anticipated in 2014/15. AstraZeneca is behind the likes of Bristol-Myers, Roche and Merck & Co in the race to develop immunotherapies - a hot new area of cancer research - but it is betting on combination treatments to help it to catch up. Immunotherapy, which harnesses the body’s immune system to fight cancer, has shown great promise in clinical trials and analysts believe that the treatments may extend patients’ lives significantly and generate tens of billions of dollars in annual sales.

A:
Drugmaker AstraZeneca forecasts faster return to growth.
****